AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 3 analysts
Fundamentals
Fundamentals institutional score is 72 using EVA spread proxy 28.3%; growth durability 29.9.
Valuation
Valuation institutional score is 99 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 67 using mean target upside 31.4%; dispersion penalty 18.7; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 63 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 11 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and valuation provide support.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 44.0% below historical median. Valuation is declining — currently in the strongly undervalued zone (z-score: -1.56). Confidence: 73%.
Live forward EPS implies next-12-month EPS of ₹183.90. Applying the stock's normalized valuation corridor produces a fair range of ₹5,914.22 to ₹8,801.45, with base value near ₹7,709.09 (+133.4% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹183.90
Forward P/E
18.0x
Base Fair Value
₹7,709.09
Fair Range
₹5,914.22 - ₹8,801.45
Upside To Base
+133.4%
Estimate Source
Live forward EPS
Growth Estimate
+20.1%
5Y Average
40.24
Current
23.47
Overvalued
47.86
Undervalued
32.16
5Y Average
26.23
Current
15.30
Overvalued
29.97
Undervalued
23.05
5Y Average
7.22
Current
4.21
Overvalued
8.25
Undervalued
6.35
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 31.2x Undervalued | -54% vs avg | +25.2% |
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.4x Undervalued | -58% vs avg | +43.2% |
CONCORD BIOTECH LIMITED CONCORDBIOPharmaceuticals | +26.2% | 24.8% | 49.1x Undervalued | -28% vs avg | -13.9% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 39.9x Undervalued | -41% vs avg | +51.8% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.6x Undervalued | -36% vs avg | -23.8% |
ASTRAZENECA PHARMA IND LT ASTRAZENPharmaceuticals | +20.4% | 8.2% | 116.9x Premium | +72% vs avg | -6.7% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 167.5x Premium | +146% vs avg | -53.0% |
SANOFI INDIA LIMITED trades at a discount (23.5x vs peer avg 68.1x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include CAPLIN POINT LAB LTD., ALIVUS LIFE SCIENCES LTD, CONCORD BIOTECH LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹472 CrMar 2026Latest net profit
₹103 CrMar 2026Latest EPS
₹44.55Mar 2026Net margin
28.3%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 736 | 515 | 491 | 469 | 511 | 464 | 524 | 515 | 536 | 406 | 475 | 420 | 472 |
| Expenses | 514 | 393 | 377 | 370 | 400 | 348 | 404 | 397 | 364 | 311 | 368 | 330 | 330 |
| Operating Profit | 212 | 112 | 104 | 90.3 | 101 | 107 | 111 | 109 | 162 | 85.8 | 97.8 | 80.8 | 134 |
| OPM % | 28.85% | 21.85% | 21.26% | 19.25% | 19.83% | 23.02% | 21.13% | 21.11% | 30.29% | 21.12% | 20.57% | 19.25% | 28.33% |
| Other Income | 25.8 | 15.5 | 10.6 | 9.4 | 3.5 | 4.8 | 2.3 | 5.9 | 3.3 | 8.7 | 4.9 | 2.8 | 4.4 |
| Interest | 0.3 | 0.7 | 0.3 | 0.4 | 0.3 | 0.4 | 0.4 | 0.4 | 0.3 | 0.4 | 0.4 | 0.6 | 0.3 |
| Depreciation | 9.7 | 9.1 | 9.2 | 9.3 | 9.1 | 9 | 9 | 9.6 | 9.6 | 9.1 | 9.1 | 9.5 | 9 |
| Profit before tax | 238 | 127 | 115 | 99.3 | 104 | 111 | 113 | 114 | 165 | 94.1 | 102 | 83 | 138 |
| Tax % | 30.71% | 36.37% | 29.67% | 29.81% | 31.1% | 21.51% | 27% | 27.06% | 27.71% | 26.14% | 25.71% | 25.66% | 25.6% |
| Net Profit | 165 | 81 | 80.6 | 69.7 | 72 | 87.2 | 82.2 | 83.3 | 120 | 69.5 | 76 | 61.7 | 103 |
| EPS in Rs | 82.67 | 53.37 | 66.08 | 59.79 | 59.31 | 44.90 | 36.69 | 39.64 | 51.89 | 30.18 | 32.99 | 26.79 | 44.55 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.